Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of HRS-4729 injection in adults with type 2 diabetes mellitus
CTR20263695Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS-4729 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Change from baseline in glycated hemoglobin. Started Oct 2026; status: active.
02
Drugs
HRS-4729
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263695.